The FDA has approved Intrarosa (prasterone), from Endoceutics Inc., to treat postmenopausal women experiencing pain during sex.
Indication: Intrarosa is the first FDA approved product containing the active ingredient prasterone, also known as dehydroepiandrosterone (DHEA), indicated to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.
Dosage and administration: Intrarosa is a once-daily vaginal insert for postmenopausal women experiencing pain during sex.
Efficacy and safety: The efficacy of Intrarosa was established in two, 12-week placebo-controlled clinical trials of 406 healthy postmenopausal women, aged 40 to 80 years, who identified moderate to severe pain during sexual intercourse as their bothersome symptom of VVA. Women were randomly assigned to receive Intrarosa or a placebo vaginal insert. Intrarosa, when compared to placebo, was shown to reduce the severity of pain experienced during sexual intercourse. The safety of Intrarosa was established in four, 12-week placebo-controlled trials and one, 52-week open-label trial.
Adverse reactions: The most common adverse reactions with Intrarosa were vaginal discharge and abnormal Pap smear.
US Food and Drug Administration. FDA approves Intrarosa for postmenopausal women experiencing pain during sex. FDA web site. November 17, 2016. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm529641.htm. Accessed November 17, 2016.
This Week's Must Reads
Must Reads in Menopause
Menopause Symptom Burden and Chronic Pain, Menopause; ePub 2019 Mar 4; Gibson, et al
Trends in Menopausal Hormone Therapy, Menopause; ePub 2018 Dec 21; Crawford, et al
Chronic Disease Risk with Vaginal Estrogen Use, Menopause; ePub 2018 Dec 17; Bhupathiraju, et al
Sleep Disturbance After Surgical Menopause, Menopause; ePub 2018 Nov 12; Cho, Kim, et al
Cardiac Autonomic Function in Midlife Women, Menopause; ePub 2018 Jun 18; Fu, et al